secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001213900-24-066327
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra achieves primary endpoint in Phase 3 dry eye trial of reproxalap; NDA resubmission planned 2024
--------------------------------------------------------------------------------

- Primary endpoint of ocular discomfort met (p=0.004) vs vehicle in 132-patient Phase 3 dry eye chamber trial.
- NDA resubmission for reproxalap anticipated in 2024; FDA review period expected ~6 months.
- Reproxalap studied in over 2,500 patients; no safety signals; mild transient instillation site discomfort most common AE.
- Option agreement with AbbVie includes $100M upfront if exercised, plus up to $300M milestones and profit/loss share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024066327/0001213900-24-066327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024066327/ea0210840-8k_aldeyra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-066327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer